Cisplatin is worldwide standard-of-care chemotherapy in muscle-invasive bladder cancer (MIBC). However, many patients develop resistance to cisplatin with no second-line treatment options currently available. A new study published on April 10, 2017 in European Urology demonstrates VAR2-mediated drug delivery as a putative second-line treatment strategy in cisplatin-resistant MIBC. Bladder cancer is the 5th most common […]
